Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

609
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
609
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Age, endocrine therapy persistence, and recurrence risk in hormone receptor-positive early breast cancer: clarifying a long-standing clinical question.

Chinese clinical oncology·2026
Same author

AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2026.

Breast care (Basel, Switzerland)·2026
Same author

AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2026.

Breast care (Basel, Switzerland)·2026
Same author

Stability of potato glycoalkaloids under heating conditions - Reactions with fatty acids.

Current research in food science·2026
Same author

AGO Breast Committee recommendations for the surgical therapy of breast cancer: Working Group on Gynecologic Cancers (AGO) update 2026.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2026
Same author

The community engagement and empowerment cycle: FAIRagro's framework to foster cultural change towards FAIR RDM practices in agrosystem science and beyond.

Journal of integrative bioinformatics·2026

Related Experiment Video

Updated: Jan 2, 2026

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

597

Prognostic and predictive markers for adjuvant therapy.

Marcus Schmidt1

  • 1Department of Obstetrics and Gynecology, University Medical Center Mainz, Mainz, Germany.

Current Opinion in Obstetrics & Gynecology
|December 14, 2019
PubMed
Summary
This summary is machine-generated.

Accurate risk assessment is crucial for early breast cancer treatment. Recent advances in gene expression, genomics, and circulating biomarkers improve prognosis and predict treatment effectiveness, enabling personalized therapy.

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.6K
Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.4K

Related Experiment Videos

Last Updated: Jan 2, 2026

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

597
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.6K
Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.4K

Area of Science:

  • Oncology
  • Genomics
  • Immunology

Background:

  • Accurate risk assessment is essential to prevent overtreatment and undertreatment in early breast cancer.
  • Adjuvant therapy decisions require reliable prognostic and predictive factors.

Purpose of the Study:

  • To review recent advancements in prognostic and predictive factors for adjuvant therapy in early breast cancer.
  • To highlight how new techniques improve risk stratification and personalize treatment.

Main Methods:

  • Review of recently published articles on prognostic and predictive factors.
  • Analysis of studies utilizing gene expression signatures, next-generation sequencing, and circulating biomarkers.
  • Evaluation of research on tumor-infiltrating lymphocytes and immune cell infiltrates.

Main Results:

  • Gene expression signatures significantly enhance prognostic accuracy, especially when combined with pathological factors like tumor size.
  • Next-generation sequencing provides deeper insights into somatic mutations, prognosis, and treatment efficacy.
  • Circulating tumor cells and cell-free DNA improve recurrence risk estimation.
  • Tumor-infiltrating lymphocytes and immune cell subtyping are critical for prognosis, particularly in triple-negative breast cancer.

Conclusions:

  • Recent studies offer improved methods for prognostication and predicting therapeutic efficacy in early breast cancer.
  • These advancements facilitate better risk stratification, leading to more tailored and effective therapies.